{"id":"doi:10.1038/s41467-021-23746-0","kind":"article","title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","authors":["Cullen NC","Leuzy A","Janelidze S","Palmqvist S","Svenningsson AL","Stomrud E","Dage JL","Mattsson-Carlgren N","Hansson O"],"author_count":9,"year":2021,"published":"2021-06-11","venue":"Nature communications","cited_by":240,"doi":"10.1038/s41467-021-23746-0","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41467-021-23746-0","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41467-021-23746-0","updated":null,"pmid":"34117234","pmcid":"PMC8196018","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC8196018/pdf","abstract":"Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly individuals. We therefore tested if plasma measurements of amyloid-β (Aβ)42/40, phospho-tau217 (P-tau217), and neurofilament light (NfL) together predict clinical deterioration in 435 CU individuals followed for an average of 4.8 ± 1.7 years in the BioFINDER study. A combination of all three plasma biomarkers and basic demographics best predicted change in cognition (Pre-Alzheimer's Clinical Composite; R 2 = 0.14, 95% CI [0.12-0.17]; P < 0.0001) and subsequent AD dementia (AUC = 0.82, 95% CI [0.77-0.91], P < 0.0001). In a simulated clinical trial, a screening algorithm combining all three plasma biomarkers would reduce the required sample size by 70% (95% CI [54-81]; P < 0.001) with cognition as trial endpoint, and by 63% (95% CI [53-70], P < 0.001) with subsequent AD dementia as trial endpoint. Plasma ATN biomarkers show usefulness in cognitively unimpaired populations and could make large clinical trials more feasible and cost-effective.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations\" by Cullen NC, Leuzy A, Janelidze S et al., https://doi.org/10.1038/s41467-021-23746-0, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}